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The von Hippel–Lindau (VHL) protein serves to recruit the hypoxia-inducible
factor alpha (HIF1a) protein under normoxia to the CUL2 E3 ubiquitin ligase
for its ubiquitylation and degradation through the proteasome. In this report,
we modify VHL to engineer an affinity-directed protein missile (AdPROM)
system to direct specific endogenous target proteins for proteolysis in mamma-
lian cells. The proteolytic AdPROM construct harbours a cameloid anti-green
fluorescence protein (aGFP) nanobody that is fused to VHL for either con-
stitutive or tetracycline-inducible expression. For target proteins, we exploit
CRISPR/Cas9 to rapidly generate human kidney HEK293 and U2OS osteosar-
coma homozygous knock-in cells harbouring GFP tags at the VPS34 (vacuolar
protein sorting 34) and protein associated with SMAD1 (PAWS1, aka
FAM83G) loci, respectively. Using these cells, we demonstrate that the
expression of the VHL-aGFP AdPROM system results in near-complete degra-
dation of the endogenous GFP-VPS34 and PAWS1-GFP proteins through
the proteasome. Additionally, we show that Tet-inducible destruction of
GFP-VPS34 results in the degradation of its associated partner, UVRAG,
and reduction in levels of cellular phosphatidylinositol 3-phosphate.
1. Introduction
The degradation of many proteins by the ubiquitin-proteasome system (UPS)
plays a fundamental role in protein turnover and the maintenance of cellular
homeostasis [1,2]. The system uses the sequential action of E1-ubiquitin-
activating enzyme, E2 ubiquitin-conjugating enzymes and E3-ubiquitin ligases
to attach ubiquitin chains onto target proteins and mark them for degradation
by the proteasome [3,4]. The human genome encodes two E1 enzymes, around
50 E2 enzymes and over 600 E3 ubiquitin ligases [5–7]. The substrate specificity
of the UPS is determined by the substrate-recognition elements within the E3
ubiquitin ligase complexes [8,9]. The Cullin RING (really interesting new
gene) E3 ubiquitin ligases (CRLs) constitute the largest family of E3 ubiquitin
ligases that contribute to the UPS [8,10,11].
The CRL family constitutes seven evolutionarily conserved members,
termed CUL1, CUL2, CUL3, CUL4A, CUL4B, CUL5 and CUL7, which share
parallel structural and catalytic features [8,12]. The CULs are bound in a com-
plex by selective adaptor and substrate-receptor subunits as well as one RING
E3 ligase protein, RBX1/2 [8,11,12]. All CRLs are activated by the covalent
attachment of a ubiquitin-like modifier termed NEDD8 through Neddylation,
which requires its cognate E1, E2 and E3 enzymes analogous to the ubiquity-
lation process [13]. A selective inhibitor of the NEDD8-activating enzyme
(E1), MLN4924, inhibits the activation of CRLs in cells [10]. The nature and
number of substrate receptor subunits for each CRL complex define the range
of targets they ubiquitylate for proteasomal degradation in cells. Upon binding
& 2016 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
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the cognate substrate receptor subunit, the CRL substrate is
positioned in proximity to the RBX1/2 RING E3 ligase
and the respective E2-Ub conjugates, which can efficiently
ubiquitylate the substrate, marking it for rapid degradation
by the proteasome [8,12,14]. For CUL1 and CUL7, SKP1
serves as an adaptor, whereas one of numerous F-BOX
domain proteins functions as a substrate receptor [12]. The
F-BOX domain associates with SKP1 in the CUL1/7-complex.
Similarly, CUL2 exploits proteins Elongin B/C as adaptors,
and VHL serves as the substrate receptor. Under normoxic
conditions, VHL binds to hydroxy-proline modified HIF1a
and brings HIF1a in close proximity to RBX1 for its ubiquity-
lation [15,16]. The VHL-BOX domain of VHL, incorporating
residues T152-H191 of human VHL, mediates its association
with the CUL2/Elongin B/C complex [15]. CUL5 functions
in an analogous way to CUL2 except that it exploits SOCS
proteins as substrate receptors [15].
Molecular studies on CRLs have established proximity-
driven ubiquitylation of substrates by RBX E3 ubiquitin ligases
as the key mode of action for their degradation [8,17]. This has
allowed the exploitation of the CRL-mediated UPS for the
development of novel therapeutics, such as proteolysis target-
ing chimeric molecules (PROTACs), which employ selective
small molecule chimeras that serve to recruit a target protein
(e.g. a protein kinase) to a substrate receptor of the CRL
system (e.g. VHL) to facilitate the CRL E3 ubiquitin ligase to
ubiquitylate the target protein, subsequently marking it for
degradation [18,19]. The successful application of some PRO-
TACs [19,20] demonstrates that the CRL system can be
exploited for degradation of target proteins as long as they
can be recruited selectively to the substrate receptors of the
CRL system.
The advancement of the CRISPR/Cas9 genome editing
methodologies has made it relatively easy to achieve gene
knockouts in somatic cells [21]. However, one key limitation
of the CRISPR/Cas9 genome editing technology is that it is
impossible to knock out genes that are essential for cell survival
or proliferation. It is estimated that there are over 1800 genes for
which achieving knockouts with conventional CRISPR/Cas9
methodology is not possible [22]. CRISPR/Cas9 can be used
to efficiently knock in GFP tags to both alleles of essential
genes provided the proximity/presence of the tag does not
adversely affect the target expression or protein function. The
fluorescence allows for rapid isolation of fluorescent-positive
cells through fluorescence-activated cell sorting (FACS) [23].
Such fluorescent-tagged proteins driven by endogenous pro-
moters not only facilitate robust localization, proteomic and
biochemical studies on the target proteins, but also form the
basis for their targeted degradation in this study.
The past few years have seen a dramatic rise in the develop-
ment and use of small (approx. 15 kDa), single chain
polypeptide antibodies derived from camelid species (often
called nanobodies) against different antigens [24–26]. Many
high-affinity and selective polypeptide nanobodies have been
generated against fluorescent proteins, including GFP, mCherry
and DSred, which selectively bind their targets with low nano-
molar affinities [24,25,27]. A key advantage of these small
polypeptide nanobodies is that they can be packaged into
cDNA plasmids for expression in multiple cell systems and
they retain their specificity and affinity for their targets. In
this study, we have employed CRISPR/Cas9 to generate cell
lines in which we have knocked in a GFP-tag on endogenous
VPS34 and PAWS1/FAM83G genes. In these cells, by using
the anti-GFP nanobody attached to VHL, we direct the
endogenously GFP-tagged VPS34 and PAWS1 to ubiquitin-
mediated destruction through the CRL machinery. VPS34 is
the only known class III phosphatidylinositol 3-kinase that gen-
erates phosphatidylinositol 3-phosphate (PI3P) on endosomal
membranes. It is essential for cell survival and plays a key
role in membrane trafficking, autophagy and intracellular sig-
nalling [28,29]. PAWS1 is a poorly characterized protein that
modulates BMP signalling and transcription [30]. By combining
the CRISPR/Cas9 genome editing technology and the CRL
ubiquitin-proteasome system, we demonstrate, in this study,
that it is possible to direct selective target proteins to near-
complete degradation. We also demonstrate that the system
represents a simple and robust means of investigating the
functional consequences of the loss of target proteins and
their associated complexes. We name this approach the
affinity-directed protein missile (AdPROM) system.
2. Results
2.1. The affinity-directed protein missile system is
effective for degradation of selective endogenous
proteins
Under normal oxygen conditions, the CUL2 E3-ligase complex
constitutively ubiquitylates and degrades the protein HIF1a,
which is hydroxylated on proline residues by prolyl hydroxyl-
ase enzymes for its recognition by VHL [8,16,31] (figure 1a).
The proximity of VHL-bound hydroxylated HIF1a to the
RING-E3 ligase RBX1 in the CUL2 machinery is sufficient for
its ubiquitylation by RBX1 [8]. We engineered the AdPROM
construct so that VHL was modified by adding an anti-GFP
(aGFP) nanobody [26] to either the N- or the C-terminus of
VHL and cloned it in to a mammalian expression pBABED
retroviral vector. In principle, upon expression of these
constructs in cells, the expression of the anti-GFP nanobody
tethered to VHL would be predicted to recruit any GFP-
tagged protein to the CUL2 E3 ligase machinery (figure 1b).
Provided the GFP-tagged protein expressed in cells is then
suitably positioned for RBX1-mediated ubiquitylation,
the AdPROM system would be predicted to cause its
ubiquitin-mediated proteasomal degradation (figure 1b).
In order to generate cell lines that harbour an endogenous
GFP-tag on the target protein, we have optimized protocols
for rapidly knocking in GFP tags onto the endogenous gene
loci, using CRISPR/Cas9. Using a simple targeting strategy
(figure 1c), we can efficiently yield homozygous GFP
knockins at either the N- or C-terminus of any gene in somatic
cells in around three weeks. We accomplished homozygous
knockins of GFP tags at the N-terminus of VPS34 in HEK293
cells, and the C-terminus of PAWS1/FAM83G in U2OS cells,
as demonstrated by immunoblotting respective extracts with
both anti-GFP antibody or antibodies recognizing endogenous
VPS34 and PAWS1 proteins (figure 1d). Addition of a GFP tag
causes disappearance of protein detection at the predicted,
native molecular weight, whereas detection is confirmed at
a higher molecular weight accounting for the additional GFP
tag (figure 1d).
Next, we introduced the AdPROM system (figure 1b) in the
GFP-VPS34 and PAWS1-GFP cells (figure 1d ), via retroviral
infections using a control vector, or vectors encoding the
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aGFP-VHL or VHL-aGFP polypeptides positioned down-
stream of a constitutive promoter (figure 1e). The expression
of endogenous GFP-VPS34 and PAWS1-GFP was then moni-
tored in cell extracts by immunoblotting with either anti-GFP
antibody or antibodies recognizing VPS34 and PAWS1
(figure 1f ). While the control vector and the vector encoding
aGFP-VHL did not result in loss of GFP-VPS34 and PAWS1-
GFP protein levels, in cells expressing VHL-aGFP, the levels
of GFP-VPS34 and PAWS1-GFP proteins were depleted to
near undetectable levels (figure 1f ). Furthermore, in HEK293
cells in which endogenous PAWS1 is not modified by a GFP
knockin, and similarly in U2OS cells in which endogenous
VPS34 is unmodified, the expression of VHL-aGFP did not
change the levels of native PAWS1 and VPS34, respectively,
suggesting that VHL-aGFP only targets GFP-tagged proteins
for destruction (figure 1f). Interestingly, the positioning of
the aGFP to the C-terminus of VHL but not the N-terminus
appears to be crucial for orientating the GFP-VPS34 and
PAWS1-GFP for the RBX1 E3 ubiquitin ligase machinery to
ubiquitylate these proteins (figure 1f ). Consequently, we
used the VHL-aGFP polypeptide as the effective orientation
for the AdPROM system for subsequent experiments.
In order to confirm that overexpression of VHL and
aGFP alone did not affect endogenously GFP-tagged proteins,
we performed immunoblotting on PAWS1-GFP U2OS cells,
which were infected with vectors harbouring GFP control,
VHL alone control, aGFP alone control or VHL-aGFP. As
expected, only VHL-aGFP expression resulted in robust
PAWS1-GFP degradation, whereas neither VHL nor aGFP on
their own were capable of mediating PAWS1-GFP destruction
(electronic supplementary material, figure S1). As aGFP alone
can still bind to the GFP-tagged proteins in cells, potentially
compromising their function in other non-degradative ways,
we have used GFP as a control for most of our studies. To
demonstrate that the substrate recruitment for AdPROM was
mediated through aGFP and increase the versatility of the
system, we replaced aGFP with an independently derived,
distinct cameloid anti-GFP nanobody, aGFP16 (electronic
supplementary material, figure 2a) [24]. The two anti-GFP
nanobodies recognize distinct structural elements within the
GFP beta-barrel structure [24,26]. The AdPROM system har-
bouring VHL-aGFP16 when expressed in cells also resulted
in efficient degradation of GFP-VPS34 and PAWS1-GFP,
whereas aGFP16 alone and VHL alone did not (electronic
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Figure 1. The affinity-directed protein missile (AdPROM) system degrades target proteins in different cell lines. (a) Schematic describes how the CUL2-E3 ligase
complex results in ubiquitylation and degradation of its native target, hydroxy-proline modified HIF1a, under normoxic conditions. (b) Schematic of the exploitation
of the CUL2 E3 ligase machinery for AdPROM using anti-GFP nanobody (aGFP) to degrade GFP-tagged proteins. (c) Strategy for rapidly knocking in a GFP tag on
target proteins in somatic cells using CRISPR/Cas9. (d ) Western blot analysis of extracts from PAWS1-GFP and GFP-VPS34 knockin U2OS and HEK293 cells, respect-
ively, using the indicated antibodies. (e) Schematic shows the application of AdPROM using pBABED-Puro (for constitutive expression) or pRetroX-TetON (for
Tet-inducible expression) retroviral infection systems to introduce the VHL-aGFP in GFP-knockin cells. ( f ) A proof-of-principle demonstration of the efficacy of
the AdPROM system in the degradation of GFP-VPS34 and PAWS1-GFP from knockin HEK293 and U2OS cells, respectively. Cells infected with control retroviruses
(GFP) or retroviruses encoding aGFP-VHL or VHL-aGFP were lysed. Extracts (20 mg protein) were subjected to resolution by SDS–PAGE and transferred to PVDF
membranes, which were analysed by western blotting with the indicated antibodies.
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supplementary material, figures S2b,c). Furthermore, aGFP16-
tethered sepharose beads efficiently pulled down endogenous
GFP-VPS34 and PAWS1-GFP, but not untagged proteins, from
cell extracts and in the process completely depleted them from
the respective flow-through extracts (electronic supplementary
material, figure S3).
2.2. AdPROM exploits the CRL ubiquitin-proteasome
pathway for target protein degradation
In order to determine whether the loss in levels of the GFP-
VPS34 and PAWS1-GFP by VHL-aGFP was indeed mediated
by the CUL2-CRL machinery, we treated the cells with the
pan-Cullin Neddylation inhibitor MLN4924. As expected,
treatment of both HEK293 and U2OS cells with MLN4924
resulted in robust inhibition of CUL2 Neddylation and stabiliz-
ation of its endogenous target, HIF1a (figure 2a). Under these
conditions, the loss in levels of GFP-VPS34 and PAWS1-GFP
was partially rescued by treatment of cells with MLN4924,
whereas, as expected, no changes were observed in control
cells (figure 2a). Importantly, the expression of VHL-aGFP
had no effect on the levels of endogenous HIF1a, suggesting
the AdPROM system does not interfere with the endogenous
CUL2 E3 ubiquitin ligase machinery (figure 2a). To verify
that the AdPROM-mediated degradation of PAWS1-GFP was
mediated by the proteasome, control cells or cells expressing
VHL-aGFP were treated with the proteasome inhibitor Borte-
zomib for 4, 10 and 24 h prior to lysis. PAWS1-GFP and total
ubiquitin levels were stabilized in a time-dependent manner
in cells expressing VHL-aGFP, whereas no significant change
was observed in control cells (figure 2b). Interestingly,
enhanced levels of PAWS1-GFP smears and total ubiquitin
were observed in VHL-aGFP expressing cells but not control
cells after 24 h of Bortezomib treatment (figure 2b),
suggesting accumulation of ubiquitylated PAWS1 upon
inhibition of the proteasome.
2.3. AdPROM can be adapted for inducible degradation
of target proteins
Having demonstrated the efficacy of the AdPROM system for
constitutive degradation of target proteins, we sought to
develop an inducible AdPROM system. We employed the
pRetroX Tet-ON retroviral tetracycline-inducible vector
system to clone VHL-aGFP16. Using this system, the GFP-
VPS34 knockin HEK293 cells infected with either control
Tet-ON empty vector or Tet-ON vector carrying VHL-
aGFP16 both displayed similar levels of GFP-VPS34 and no
detectable levels of VHL-aGFP16 in the absence of doxycycline
(figure 3). In control cells, as expected, a time course of doxycy-
cline treatment over 20 h did not alter the levels of endogenous
GFP-VPS34, its associated partner UVRAG, VHL or GAPDH
proteins. In Tet-ON VHL-aGFP16 infected cells, doxycycline
treatment induced the expression of VHL-aGFP16 in a time-
dependent manner, with detectable levels observed at 2 h
(figure 3). The increased levels of VHL-aGFP16 expression
correlated with reduction in levels of GFP-VPS34 protein in a
time-dependent manner, with reduced GFP-VPS34 levels rela-
tive to untreated controls detected at 2 h after doxycycline
treatment and sustained at the lowest levels after 6 h
(figure 3). Excitingly, the expression of endogenous UVRAG,
a regulatory component of the VPS34 kinase complex, mir-
rored the degradation of GFP-VPS34, suggesting that an
inducible AdPROM has the potential to destroy protein com-
plexes when individual components are targeted (figure 3).
The levels of GAPDH employed as controls were unaffected by
doxycycline-induced expression of VHL-aGFP16 (figure 3).
These observations suggest that the AdPROM system can be
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Figure 2. Inhibition of Cullin Neddylation and the proteasome rescues protein degradation through AdPROM: (a) retroviral infections of HEK293 and U2OS cells,
harbouring GFP-VPS34 and PAWS1-GFP knockins, respectively, were performed to allow the expression of either the control (GFP) or VHL-aGFP polypeptide. Infected
cells were then treated with either DMSO or the pan-Cullin Neddylation inhibitor MLN4924 (1 mM) for 6 h, as indicated. Extracts (20 mg protein) were resolved by
SDS–PAGE, transferred to PVDF membranes and subjected to western blotting for PAWS1, VPS34, HIF1a and Cullin2 expression as shown. GAPDH was included as a
loading control. (b) Control (GFP) or VHL-aGFP PAWS1-GFP cells described in (a) were treated with 10 mM Bortezomib for 0, 4, 10 or 24 h prior to lysis. Extracts
(20 mg protein) were resolved by SDS–PAGE, transferred to PVDF membranes and subjected to western blotting using antibodies against PAWS1, total ubiquitin
and GAPDH control as indicated.
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adapted to achieve inducible degradation of target proteins,
which could be part of pre-assembled complexes, the disrup-
tion of which can provide mechanistic insights that a
constitutive degradation system might not.
2.4. The AdPROM-mediated degradation of GFP-VPS34
inhibits VPS34 function in cells
We sought to investigate whether AdPROM-mediated indu-
cible degradation of endogenous GFP-VPS34 affected its
cellular function. The catalytic subunit of the class III phos-
phatidylinositol 3-kinase, VPS34 catalyses the generation of
PI3P, which accumulates primarily at the endosomal mem-
branes [32,33]. The endosomal PI3P then serves to recruit
proteins containing FYVE and PX domains to mediate down-
stream signalling. The cellular PI3P can be visualized using
fluorescent probes attached to a PX domain. In this study,
we used the PX domain of p40phox chemically conjugated
to Alexa Fluor 488 [34]. A PI3P-interaction deficient PX
domain mutant conjugated to Alexa Fluor 594, employed as
negative control, enabled visualization of both wild-type
and mutant PX probes in the same samples (figure 4a).
Using these fluorescent probes, we demonstrate that treating
GFP-VPS34 cells infected with Tet-ON control vector with
doxycycline for 24 h, which does not degrade GFP-VPS34
(electronic supplementary material, figure S4), did not lead to
changes in the PI3P punctate signal compared with untreated
controls, whereas cells treated with VPS34-IN1, a selective
inhibitor of VPS34, displayed near-complete loss in PI3P
puncta (figure 4a). Under identical conditions, as expected,
no changes were seen with the PX mutant probe (figure 4a).
In GFP-VPS34 cells infected with VHL-aGFP16 Tet-ON (indu-
cible AdPROM), treatment of doxycycline for 24 h, which
results in robust degradation of GFP-VPS34 (electronic sup-
plementary material, figure S4), resulted in near-complete
loss in the PI3P punctate signal compared with untreated
cells (figure 4b). This loss in PI3P puncta was comparable
with that observed in cells treated with VPS34-IN1
(figure 4b). These observations suggest that AdPROM-induced
degradation of GFP-VPS34 impacts the cellular function of
VPS34, which is at least comparable with its inhibition using
small molecule inhibitors.
3. Discussion
In this report, we describe a simple, yet robust methodology for
targeted degradation of endogenous proteins in cells. By com-
bining the efficiency of CRIPSR/Cas9 genome editing to
rapidly tag endogenous proteins with GFP, and using a
single vector in which anti-GFP nanobody is tethered to VHL
to target the GFP-tagged proteins for CRL-mediated proteaso-
mal degradation, we provide proof-of-principle evidence that
the AdPROM system can target selective proteins and
efficiently degrade them in cells, either constitutively or in a
Tet-inducible manner.
With the VHL-aGFP AdPROM, we achieved robust
degradation of GFP-VPS34 and PAWS1-GFP knockin pro-
teins in HEK293 and U2OS cells, respectively. Interestingly,
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Figure 3. Adapting AdPROM for tetracycline-inducible degradation of target proteins: GFP-VPS34 knockin HEK293 cells were first infected with the pRetroX-Tet-ON
advanced vector (Clontech) and selected for the expression of Tet-transactivator. Cells were then infected with either pRetroX-Tight empty vector control or pRetroX-
Tight vector encoding VHL-aGFP16. Cells were then treated with 2 mg ml21 doxycycline for the indicated time points prior to lysis. Extracts (20 mg protein) were
resolved by SDS–PAGE, transferred to PVDF membranes and subjected to western blotting, using antibodies against GFP, VPS34, UVRAG and VHL, as indicated. Anti-
GAPDH antibody was included as a loading control.
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aGFP-VHL did not lead to degradation of these proteins,
suggesting that this orientation is incapable of recruiting
the target proteins close to RBX1 in the CUL2-complex for
ubiquitylation. We have shown that the degradation of
GFP-VPS34 resulted in the loss of its physiological function
as judged by reduction in total cellular PI3P levels. Because
of the structural similarities between GFP and yellow fluor-
escent protein (YFP), the anti-GFP nanobodies that we have
employed in this study also bind YFP. We have been able
to extend the use of VHL-aGFP and VHL-aGFP16 AdPROMs
to successfully degrade many other target proteins in cells in
which GFP and YFP tags have been knocked in on the target
gene loci using CRISPR/Cas9. GFP and YFP knockins are
often exploited in cell and animal models as reporters for
protein expression, localization and distribution, and to
identify interacting partners through proteomic approaches.
In order to study the degradation of CUL2 components,
including VHL itself, an AdPROM construct harbouring a
different CULLIN receptor is recommended.
The proximity-driven ubiquitylation and degradation of
target proteins by the CRL ubiquitin-proteasome pathway
have also been exploited by PROTACs, which use small,
cell-permeable molecules to bring target proteins to the CRL-
machinery [18,19]. Because PROTACs can be time consuming
and expensive to develop, AdPROMs similar to the one we
have described could be exploited to rapidly test the druggabil-
ity of potential targets as a first step to developing PROTACs.
The inhibition of Cullin Neddylation by MLN4924 and the
proteasome by Bortezomib could be exploited to manipulate
target protein degradation by the AdPROM system that uses
the CRL machinery. Isolation and identification of ubiquity-
lated proteins upon proteasomal inhibition could potentially
uncover components of the target protein complex, as target-
ing VPS34 degradation by AdPROM also resulted in the
degradation of its associated partner UVRAG.
One limitation of the AdPROM degradation system in
its current form is the length of the affinity probe that can
be tethered to VHL without the affinity probe itself
being recognized as a substrate by the CUL2 E3 ubiquitin
ligase machinery. Because anti-GFP nanobody is tolerated,
as observed by its robust expression, it is perhaps safe to
assume that a length of around 100 amino acids for the
affinity probe is tolerated. More work is being done to under-
stand the minimum determinants of affinity probe tolerance
by the system, and to determine if the AdPROM system
could be refined to achieve better and more efficient target
protein degradation.
While we have focused on target protein degradation in
this report, the potential applications of the AdPROM system
are vast. In principle, an effective AdPROM system consists
of at least two linked elements: an ‘affinity probe’ (such as
anti-GFP nanobody in this case) that selectively targets desired
proteins; and the ‘payload’, which could constitute a destruc-
tive signal (e.g. substrate receptor subunit of any CRL-E3
ligase machinery for target protein degradation), an enzyme
(for target protein modification), a subcellular localization
signal or any combination of these. The advances in cameloid
polypeptide antibody technology will, in the near future,
make highly selective nanobodies against specific proteins
available that could be exploited as ‘affinity probes’ for
AdPROM; as could any protein interaction domain or a
signal reader domain. These would bypass the requirement
for knocking in fluorescent tags on endogenous proteins. The
choice for ‘payload’ could be vast and be applied to address
many different research questions on uncovering target protein
function and regulation. The simplicity, broad applicability
and versatility of the AdPROM system has the potential to
make it into an effective tool for investigation of specific
endogenous protein isoforms at desired cellular locations, in
any cell line.
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Figure 4. Degradation of VPS34 through AdPROM results in loss of function. (a) GFP-VPS34 knockin HEK293 cells expressing the Tet-transactivator were infected
with pRetroX-Tight empty vector control. Following selection, cells were seeded onto glass coverslips and either left untreated or treated with doxycycline
(2 mg ml21; 24 h) or VPS34-IN1 (2.5 mM, 1 h). Cells were permealized in liquid nitrogen, and fixed in 3.7% (w/v) paraformaldehyde before staining with fluor-
escently labelled selective PI3P binding (green) and interaction deficient (red) probes as described in the Material and methods section. Samples were mounted on
microscopy slides with mounting media containing DAPI (blue). (b) As in (a), except that the cells were infected with pRetroX-Tight vector encoding VHL-aGFP16.
Images were taken using DeltaVision microscopy imaging systems (GE Healthcare) at 60 magnification.
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4. Material and methods
4.1. Plasmids
A modified Cas9 nickase system [35] was used for the gener-
ation of VPS34 and PAWS1-GFP knockins. Optimal sgRNA
pairs were identified and chosen on the basis of being as
close as possible to the point of GFP insertion while having a
low combined off-targeting score (VPS34-sgRNA1: GCTACA
TCTATAGTTGTGACC (DU52071); sgRNA2: GCCCCATCGC
ACCGTCTGCAA (DU52082); PAWS1-sgRNA1: GCCTCATC
GGATTCTAAACGG (DU48793); sgRNA2: GCCACTGGC
TACCGCCCGTCC (DU48826)). Complementary oligos with
BbsI compatible overhangs were designed for each and these
dsDNA guide inserts ligated into BbsI-digested target vectors;
the antisense guides (sgRNA2) were cloned onto the spCas9
D10A expressing pX335 vector (Addgene plasmid no. 42335)
and the sense guides (sgRNA1) into the puromycin-selectable
pBABED P U6 plasmid (Dundee-modified version of the
original Cell Biolabs pBABE plasmid). Donor constructs
(VPS34-DU52175 and PAWS1-DU48585) consisting of GFP
flanked by approximately 500 bp homology arms were syn-
thesized by GeneArt (Life Technologies); each donor was
engineered to contain sufficient silent mutations to prevent rec-
ognition and cleavage by Cas9 nuclease. The cDNAs encoding
GFP (DU32961), anti-GFP nanobodies (aGFP-DU54218;
aGFP16-DU54238) [24,27], human VHL (DU54023), aGFP-
VHL (DU54023), VHL-aGFP (DU54221) and VHL-aGFP16
(DU54294) were cloned into pBABED-Puro vectors (Cell
Biolabs, modified) for constitutive expression and pRetroX-
pTight Tet-ON vectors (Clontech) for tetracycline-inducible
expression. The retroviral expression system vectors pCMV-
Gag-Pol and pCMV-VSVG constructs were from Clontech.
All DNA constructs were verified by DNA sequencing,
performed by the DNA Sequencing and Services (MRCPPU,
College of Life Sciences, University of Dundee, Scotland,
http://www.dnaseq.co.uk) using Applied Biosystems Big-
Dye v. 3.1 chemistry on an Applied Biosystems model 3730
automated capillary DNA sequencer. All constructs are avail-
able to request from the MRC-PPU reagents webpage
(http://mrcppureagents.dundee.ac.uk) and the unique identi-
fier (DU) numbers indicated above provide direct links to the
cloning and sequence details.
4.2. Antibodies
Antibodies against GFP (S268B), PAWS1 (S876C) [30] and
VPS34 (S672B) were generated in sheep and affinity purified
by the Division of Signal Transduction Therapy at the Univer-
sity of Dundee. Rat anti-GFP antibody was purchased from
Chromotek (cat.: 3H9). Rabbit anti-GAPDH (cat.: 2118) and
anti-VHL (cat.: 2738 and 68547) antibodies were purchased
from CST. Anti-HIF1a antibody (cat.: 610959) was purchased
from BD Transduction Laboratories. Rabbit anti-Ubiquitin anti-
body (cat.: 106260) was obtained from Dako. CUL2 antibody
was from Invitrogen (cat.: 51-1800) and UVRAG antibody
was from MBL (cat.: M160-3). For western blot analysis, all
primary antibodies were used at 1 : 1000 dilution, except for
anti-GFP, anti-Ubiquitin, anti-PAWS1 and anti-GAPDH anti-
bodies, which were used at 1 : 5000 dilution. Horseradish
peroxidase (HRP)-coupled secondary antibodies (1 : 5000)
were obtained from Santa Cruz.
4.3. Cell culture
All cells (HEK293, U2OS and 293-FT) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM; Gibco) sup-
plemented with 10% fetal bovine serum (Hyclone), 1%
penicillin/streptomycin (Lonza) and 2 mM L-glutamine
(Lonza), and maintained at 378C in a humidified incubator
at 5% CO2. Cells were exposed to compounds or different
stimuli as described in the appropriate figure legends. For ret-
roviral production, pBABED and pRetroX retroviral plasmids
(6 mg) encoding appropriate proteins were co-transfected
with pCMV-gag-pol (4 mg) and pCMV-VSV-G (2 mg) in a
10 cm diameter dish of 70% confluent 293-FT cells. Briefly,
plasmids were mixed in 0.6 ml Optimem (Life Technologies)
to which 24ml of 1 mg ml21 polyethylenimine (Polysciences)
diluted in 25 mM HEPES pH 7.5 was added. Following 15 s
of vortexing and incubation for 15 min at room temperature,
the resulting mixture was applied dropwise to the 293-FT
cells. The medium was replaced 16 h post-transfection with
fresh medium, and retroviruses were collected in the
growth medium 24 h later, and filtered using 0.45 mm filters.
Target cells (approx. 60% confluent) were infected with
the optimized titre of retrovirus medium supplemented
with 10 mg ml21 polybrene (Sigma) for 24 h and selected
for infection with 2 mg ml21 puromycin thereafter.
For lysis, cells were washed twice in ice-cold phosphate-
buffered saline (PBS), scraped on ice in lysis buffer (50 mM
Tris–HCl pH 7.5, 0.27 M sucrose, 150 mM NaCl, 1 mM
EGTA, 1 mM EDTA, 1 mM sodium orthovanadate, 1 mM
sodium b-glycerophosphate, 50 mM sodium fluoride, 5 mM
sodium pyrophosphate, 1% (v/v) Triton X-100 and 0.5% Non-
idet P-40) supplemented with complete protease inhibitors
(one tablet per 25 ml; Roche) and either 0.1% b-mercaptoetha-
nol (Sigma) or 50 mM iodoacetamide (Sigma) to inhibit the
DUBs where indicated in the figure legends. Cell extracts
were either cleared and processed immediately or snap-
frozen in liquid nitrogen and stored at 2808C. The protein
concentration was determined in a 96-well format using
Bradford protein assay reagent (Pierce).
4.4. Generation of GFP-VPS34 and PAWS1-GFP knock-in
cells using CRISPR/Cas9 genome editing
HEK293 and U2OS cells were transfected with vectors encod-
ing a pair of guide RNAs (pBABED-Puro-sgRNA1 and
pX335-CAS9-D10A-sgRNA2) targeting around either the
start codon of VPS34 or the stop codon of PAWS1 (1 mg each)
respectively, along with the respective donor plasmids carry-
ing the GFP knockin insert (3 mg). 16 h post-transfection,
cells were treated with puromycin (2 mg ml21) for 2 days.
The transfection and puromycin treatment process was
repeated one more time. Cells were then sorted by flow cyto-
metry and single GFP-positive cell clones were plated on
individual wells of two 96-well plates. Viable clones were
expanded, and integration of GFP at the target locus was veri-
fied by western blotting and genomic sequencing of the
targeted locus.
4.5. SDS–PAGE and western blotting
Reduced protein extracts (typically 10–20mg protein unless
stated otherwise) or immunoprecipitates (IPs) were separated
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on 8% SDS–PAGE gels, or 4–12% NuPAGE bis–tris precast
gels (Invitrogen) by electrophoresis. Proteins were then trans-
ferred onto polyvinylidene fluoride (PVDF) membranes
(Millipore). Membranes were blocked in 5% (w/v) non-fat
milk (Marvel) in TBS-T (50 mM Tris–HCl pH 7.5, 150 mM
NaCl, 0.2% Tween-20) and incubated overnight at 4 8C in 5%
BSA-TBS-T or 5% milk-TBS-T with the appropriate primary
antibodies. For ubiquitin blots, membranes were denatured
in 6 M guanidine hydrochloride (6 M guanidine HCl, 20 mM
Tris–HCl pH 7.5) after transfer just prior to blocking [36].
Membranes were then washed in TBS-T and incubated with
HRP-conjugated secondary antibodies in 5% milk-TBS-T for
1 h, before a further washing in TBS-T and detection using
enhanced chemiluminescence reagent (Thermo Scientific)
and exposure on medical X-ray films (Konica Minolta) as
described previously [37–39].
4.6. PI3P staining using a fluorescent-labelled selective
PI3P binding PX domain
For PI3P staining, GST-tagged PX domain (residues 1–148 of
p40phox) was expressed in Escherichia coli (BL21) and purified
over a glutathione column using standard procedures. The
recombinant protein was then conjugated to Alexa Fluor 488
as per the manufacturer’s protocol. For staining, following
doxycycline treatment, GFP-VPS34 knockin HEK293 cells
were washed two times with ice-cold PBS and two times
with ice-cold glutamate buffer (25 mM HEPES pH 7.4,
25 mM KCl, 2.5 mM Mg-acetate, 5 mM EGTA, 150 mM K-
glutamate). Coverslips were snap-frozen in liquid nitrogen
and thawed. Coverslips were washed two times more with
ice-cold glutamate buffer before fixing with 3.7% (w/v) paraf-
ormaldehyde (PFA) in 200 mM HEPES pH 7.4 for 30 min at RT.
PFA was quenched by two washes and one 10 min incubation
in DMEM containing 10 mM HEPES pH 7.4. Samples were
washed twice in blocking buffer (1% (w/v) BSA in PBS)
before being incubated in blocking buffer for 15 min. Cover-
slips were incubated for 1 h at RT with 5 mg ml21 PX
domain-Alexa Fluor-488 conjugate (diluted in blocking
buffer) and washed three times in blocking buffer. Coverslips
were washed once more in ddH2O prior to mounting with
ProLong Gold antifade mountant. Selectivity was conferred
through counter-staining with a PI3P interaction deficient
mutant PX domain probe chemically conjugated to Alexa
Fluor 594 [34]. Images were captured using DeltaVision
Imaging Systems (GE Healthcare) at 60 magnification.
Authors’ contributions. L.J.F. performed all the experiments, collected and
analysed data and contributed to the manuscript. T.M. designed
strategies and developed methodologies for, and generated, all
CRIPSR/Cas9 knockin constructs as well as AdPROM constructs.
P.B., A.H. and A.R.-F. generated the GFP and YFP knockin cells
used in this study. G.P.S. conceived the project, analysed the data
and wrote the manuscript.
Competing interests. We declare we have no competing interests.
Funding. This study was funded by the UK Medical Research Council
(grant number MC_UU_12016/3). L.J.F. and P.B. are supported
by the UK MRC Prize PhD studentships. G.P.S. is supported by
the UK Medical Research Council and the pharmaceutical companies
supporting the DSTT (AstraZeneca, Boehringer-Ingelheim,
GlaxoSmithKline, Merck-Serono, Pfizer and Janssen).
Acknowledgements. We thank M. Rout (Rockefeller, USA) for generously
sending us recombinant anti-GFP nanobodies. We thank K. Wu for
help with microscopy. We thank S. Virdee, A. Ciulli and D. R. Alessi
for helpful discussions. We thank I. Ganley and N. Malik for gener-
ously providing the WT and mutant PI3P fluorescent probes. We
thank L. Fin, J. Stark and A. Muir for help with tissue culture, the
staff at the Sequencing Service (School of Life Sciences, University of
Dundee, UK) for DNA sequencing, and the protein and antibody
production and cloning teams at the Division of Signal Transduc-
tion Therapy (DSTT; University of Dundee) coordinated by
H. McLauchlan and J. Hastie.
References
1. Nandi D, Tahiliani P, Kumar A, Chandu D. 2006
The ubiquitin-proteasome system. J. Biosci. 31,
137–155. (doi:10.1007/BF02705243)
2. Roos-Mattjus P, Sistonen L. 2004 The ubiquitin-
proteasome pathway. Ann. Med. 36, 285–295.
(doi:10.1080/07853890310016324)
3. Pickart CM, Eddins MJ. 2004 Ubiquitin: structures,
functions, mechanisms. Biochim. Biophys. Acta
1695, 55–72. (doi:10.1016/j.bbamcr.2004.09.019)
4. Scheffner M, Nuber U, Huibregtse JM. 1995 Protein
ubiquitination involving an E1-E2-E3 enzyme
ubiquitin thioester cascade. Nature 373, 81–83.
(doi:10.1038/373081a0)
5. Li W, Bengtson MH, Ulbrich A, Matsuda A, Reddy
VA, Orth A, Chanda SK, Batalov S, Joazeiro CAP.
2008 Genome-wide and functional annotation of
human E3 ubiquitin ligases identifies MULAN, a
mitochondrial E3 that regulates the organelle’s
dynamics and signaling. PLoS ONE 3, e1487.
(doi:10.1371/journal.pone.0001487)
6. Wenzel DM, Stoll KE, Klevit RE. 2011 E2s:
structurally economical and functionally replete.
Biochem. J. 433, 31–42. (doi:10.1042/BJ20100985)
7. Zhao B, Bhuripanyo K, Schneider J, Zhang K,
Schindelin H, Boone D, Yin J. 2012 Specificity of the
E1-E2-E3 enzymatic cascade for ubiquitin C-terminal
sequences identified by phage display. ACS Chem.
Biol. 7, 2027–2035. (doi:10.1021/cb300339p)
8. Bulatov E, Ciulli A. 2015 Targeting Cullin-RING E3
ubiquitin ligases for drug discovery: structure,
assembly and small-molecule modulation. Biochem.
J. 467, 365–386. (doi:10.1042/BJ20141450)
9. Jackson PK, Eldridge AG, Freed E, Furstenthal L, Hsu
JY, Kaiser BK, Reimann JDR. 2000 The lore of the
RINGs: substrate recognition and catalysis by
ubiquitin ligases. Trends Cell Biol. 10, 429–439.
(doi:10.1016/S0962-8924(00)01834-1)
10. Soucy TA et al. 2009 An inhibitor of NEDD8-activating
enzyme as a new approach to treat cancer. Nature
458, 732–736. (doi:10.1038/nature07884)
11. Zhao Y, Sun Y. 2013 Cullin-RING ligases as attractive
anti-cancer targets. Curr. Pharm. Des. 19, 3215–
3225. (doi:10.2174/13816128113199990300)
12. Zheng N et al. 2002 Structure of the Cul1-Rbx1-
Skp1-F boxSkp2 SCF ubiquitin ligase complex.
Nature 416, 703–709. (doi:10.1038/416703a)
13. Enchev RI, Schulman BA, Peter M. 2015 Protein
neddylation: beyond cullin-RING ligases. Nat. Rev.
Mol. Cell Biol. 16, 30–44. (doi:10.1038/nrm3919)
14. Duda DM, Scott DC, Calabrese MF, Zimmerman ES,
Zheng N, Schulman BA. 2011 Structural regulation
of cullin-RING ubiquitin ligase complexes. Curr.
Opin. Struct. Biol. 21, 257–264. (doi:10.1016/j.sbi.
2011.01.003)
15. Kamura T, Maenaka K, Kotoshiba S, Matsumoto M,
Kohda D, Conaway RC, Conaway JW, Nakayama KI.
2004 VHL-box and SOCS-box domains determine
binding specificity for Cul2-Rbx1 and Cul5-Rbx2
modules of ubiquitin ligases. Genes Dev. 18,
3055–3065. (doi:10.1101/gad.1252404)
16. Yu F, White SB, Zhao Q, Lee FS. 2001 HIF-1alpha
binding to VHL is regulated by stimulus-sensitive
proline hydroxylation. Proc. Natl Acad. Sci. USA 98,
9630–9635. (doi:10.1073/pnas.181341498)
17. Bosu DR, Kipreos ET. 2008 Cullin-RING ubiquitin
ligases: global regulation and activation cycles.
Cell Div. 3, 7. (doi:10.1186/1747-1028-3-7)
18. Buckley DL, Gustafson JL, Van Molle I, Roth AG, Tae
HS, Gareiss PC, Jorgensen WL, Ciulli A, Crews CM.
rsob.royalsocietypublishing.org
Open
Biol.6:160255
8
 on October 31, 2016http://rsob.royalsocietypublishing.org/Downloaded from 
2014 Small-molecule inhibitors of the interaction
between the E3 ligase VHL and HIF1a. Angew.
Chem. Int. Ed. Engl. 51, 11 463–11 467. (doi:10.
1002/anie.201206231)
19. Sakamoto KM, Kim KB, Kumagai A, Mercurio F,
Crews CM, Deshaies RJ. 2001 Protacs: chimeric
molecules that target proteins to the Skp1-Cullin-F
box complex for ubiquitination and degradation.
Proc. Natl Acad. Sci. USA 98, 8554–8559. (doi:10.
1073/pnas.141230798)
20. Zengerle M, Chan KH, Ciulli A. 2015 Selective small
molecule induced degradation of the BET
bromodomain protein BRD4. ACS Chem. Biol. 10,
1770–1777. (doi:10.1021/acschembio.5b00216)
21. Sander JD, Joung JK. 2014 CRISPR-Cas systems for
editing, regulating and targeting genomes. Nat.
Biotechnol. 32, 347–355. (doi:10.1038/nbt.2842)
22. Wang T, Birsoy K, Hughes NW, Krupczak KM, Post Y,
Wei JJ, Lander ES, Sabatini DM. 2015 Identification
and characterization of essential genes in the
human genome. Science 350, 1096–1101. (doi:10.
1126/science.aac7041)
23. Rojas-Fernandez A, Herhaus L, Macartney T,
Lachaud C, Hay RT, Sapkota GP. 2015 Rapid
generation of endogenously driven transcriptional
reporters in cells through CRISPR/Cas9. Sci. Rep. 5,
9811. (doi:10.1038/srep09811)
24. Fridy PC et al. 2014 A robust pipeline for rapid
production of versatile nanobody repertoires. Nat.
Methods 11, 1253–1260. (doi:10.1038/nmeth.3170)
25. Helma J, Cardoso MC, Muyldermans S, Leonhardt H.
2015 Nanobodies and recombinant binders in cell
biology. J. Cell Biol. 209, 633–644. (doi:10.1083/
jcb.201409074)
26. Kirchhofer A et al. 2010 Modulation of protein
properties in living cells using nanobodies. Nat.
Struct. Mol. Biol. 17, 133–138. (doi:10.1038/
nsmb.1727)
27. Rothbauer U, Zolghadr K, Muyldermans S, Schepers
A, Cardoso MC, Leonhardt H. 2008 A versatile
nanotrap for biochemical and functional studies
with fluorescent fusion proteins. Mol. Cell
Proteomics 7, 282–289. (doi:10.1074/mcp.
M700342-MCP200)
28. Funderburk SF, Wang QJ, Yue Z. 2010 The Beclin
1-VPS34 complex–at the crossroads of autophagy
and beyond. Trends Cell Biol. 20, 355–362. (doi:10.
1016/j.tcb.2010.03.002)
29. Schu PV, Takegawa K, Fry M, Stack J, Waterfield M,
Emr S. 1993 Phosphatidylinositol 3-kinase
encoded by yeast VPS34 gene essential for protein
sorting. Science 260, 88–91. (doi:10.1126/science.
8385367)
30. Vogt J, Dingwell KS, Herhaus L, Gourlay R,
Macartney T, Campbell D, Smith JC, Sapkota GP.
2014 Protein associated with SMAD1 (PAWS1/
FAM83G) is a substrate for type I bone
morphogenetic protein receptors and modulates
bone morphogenetic protein signalling. Open Biol.
4, 130210. (doi:10.1098/rsob.130210)
31. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M,
Conaway RC, Conaway JW. 2000 Activation of
HIF1alpha ubiquitination by a reconstituted von
Hippel-Lindau (VHL) tumor suppressor complex.
Proc. Natl Acad. Sci. USA 97, 10 430–10 435.
(doi:10.1073/pnas.190332597)
32. Bago R et al. 2014 Characterization of VPS34-IN1, a
selective inhibitor of Vps34, reveals that the
phosphatidylinositol 3-phosphate-binding SGK3
protein kinase is a downstream target of class III
phosphoinositide 3-kinase. Biochem. J. 463,
413–427. (doi:10.1042/BJ20140889)
33. Gillooly DJ, Morrow IC, Lindsay M, Gould R,
Bryant NJ, Gaullier J-M, Parton RG, Stenmark H.
2000 Localization of phosphatidylinositol
3-phosphate in yeast and mammalian cells.
EMBO J. 19, 4577–4588. (doi:10.1093/emboj/19.
17.4577)
34. Kanai F, Liu Hui, Field Seth J., Akbary Hares, Matsuo
T, Brown GE, Cantley LC, Yaffe MB. 2001 The PX
domains of p47phox and p40phox bind to lipid
products of PI(3)K. Nat. Cell Biol. 3, 675–678.
(doi:10.1038/35083070)
35. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA,
Zhang F. 2013 Genome engineering using the
CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308.
(doi:10.1038/nprot.2013.143)
36. Emmerich CH, Cohen P. 2015 Optimising
methods for the preservation, capture and
identification of ubiquitin chains and
ubiquitylated proteins by immunoblotting.
Biochem. Biophys. Res. Commun. 466, 1–14.
(doi:10.1016/j.bbrc.2015.08.109)
37. Herhaus L, Perez-Oliva AB, Cozza G, Gourlay R,
Weidlich S, Campbell DG, Pinna LA, Sapkota GP.
2015 Casein kinase 2 (CK2) phosphorylates the
deubiquitylase OTUB1 at Ser16 to trigger its nuclear
localization. Sci. Signal. 8, ra35. (doi:10.1126/
scisignal.aaa0441)
38. Herhaus L et al. 2014 USP15 targets ALK3/BMPR1A
for deubiquitylation to enhance bone
morphogenetic protein signalling. Open Biol. 4,
140065. (doi:10.1098/rsob.140065)
39. Herhaus L, Al-Salihi M, Macartney T, Weidlich S,
Sapkota GP. 2013 OTUB1 enhances TGFbeta
signalling by inhibiting the ubiquitylation and
degradation of active SMAD2/3. Nat. Commun. 4,
2519. (doi:10.1038/ncomms3519)
rsob.royalsocietypublishing.org
Open
Biol.6:160255
9
 on October 31, 2016http://rsob.royalsocietypublishing.org/Downloaded from 
